These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39039982)

  • 41. CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors
    Fang H; Zhao X; Gu X; Sun H; Cheng R; Zhong Z; Deng C
    Biomacromolecules; 2020 Jan; 21(1):104-113. PubMed ID: 31532629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
    Ganesh S; Iyer AK; Morrissey DV; Amiji MM
    Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles.
    Andreana I; Chiapasco M; Bincoletto V; Digiovanni S; Manzoli M; Ricci C; Del Favero E; Riganti C; Arpicco S; Stella B
    Drug Deliv Transl Res; 2024 Aug; 14(8):2100-2111. PubMed ID: 38709442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting hyaluronic acid family for cancer chemoprevention and therapy.
    Lokeshwar VB; Mirza S; Jordan A
    Adv Cancer Res; 2014; 123():35-65. PubMed ID: 25081525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
    Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
    J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography.
    Feng Q; Zhang Y; Zhang W; Shan X; Yuan Y; Zhang H; Hou L; Zhang Z
    Acta Biomater; 2016 Jul; 38():129-42. PubMed ID: 27090593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An insight on hyaluronic acid in drug targeting and drug delivery.
    Yadav AK; Mishra P; Agrawal GP
    J Drug Target; 2008 Feb; 16(2):91-107. PubMed ID: 18274931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advantage of hyaluronic acid for anti-cancer application: a review of "3S" transition approach.
    Zhong W; Pang L; Feng H; Dong H; Wang S; Cong H; Shen Y; Bing Y
    Carbohydr Polym; 2020 Jun; 238():116204. PubMed ID: 32299556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery.
    Hang C; Zou Y; Zhong Y; Zhong Z; Meng F
    Colloids Surf B Biointerfaces; 2017 Oct; 158():547-555. PubMed ID: 28743090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels.
    Liang K; Ng S; Lee F; Lim J; Chung JE; Lee SS; Kurisawa M
    Acta Biomater; 2016 Mar; 33():142-52. PubMed ID: 26785145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyaluronic Acid-Coated Nanomedicine for Targeted Cancer Therapy.
    Kim K; Choi H; Choi ES; Park MH; Ryu JH
    Pharmaceutics; 2019 Jun; 11(7):. PubMed ID: 31262049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.
    Platt VM; Szoka FC
    Mol Pharm; 2008; 5(4):474-86. PubMed ID: 18547053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies.
    Negi LM; Talegaonkar S; Jaggi M; Verma AK; Verma R; Dobhal S; Kumar V
    Colloids Surf B Biointerfaces; 2014 Nov; 123():610-5. PubMed ID: 25454755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery.
    Chen Z; Li Z; Lin Y; Yin M; Ren J; Qu X
    Chemistry; 2013 Jan; 19(5):1778-83. PubMed ID: 23303570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Redox-Responsive and Dual-Targeting Hyaluronic Acid-Methotrexate Prodrug Self-Assembling Nanoparticles for Enhancing Intracellular Drug Self-Delivery.
    Zhang Y; Li Y; Tian H; Zhu Q; Wang F; Fan Z; Zhou S; Wang X; Xie L; Hou Z
    Mol Pharm; 2019 Jul; 16(7):3133-3144. PubMed ID: 31198046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy.
    Li M; Sun J; Zhang W; Zhao Y; Zhang S; Zhang S
    Carbohydr Polym; 2021 Jan; 251():117103. PubMed ID: 33142641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles.
    Mizrahy S; Goldsmith M; Leviatan-Ben-Arye S; Kisin-Finfer E; Redy O; Srinivasan S; Shabat D; Godin B; Peer D
    Nanoscale; 2014 Apr; 6(7):3742-52. PubMed ID: 24569711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Binding and Internalization in Receptor-Targeted Carriers: The Complex Role of CD44 in the Uptake of Hyaluronic Acid-Based Nanoparticles (siRNA Delivery).
    Rios de la Rosa JM; Pingrajai P; Pelliccia M; Spadea A; Lallana E; Gennari A; Stratford IJ; Rocchia W; Tirella A; Tirelli N
    Adv Healthc Mater; 2019 Dec; 8(24):e1901182. PubMed ID: 31738017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Self-assembled hyaluronic acid nanoparticles: Implications as a nanomedicine for treatment of type 2 diabetes.
    Rho JG; Han HS; Han JH; Lee H; Nguyen VQ; Lee WH; Kwon S; Heo S; Yoon J; Shin HH; Lee EY; Kang H; Yang S; Lee EK; Park JH; Kim W
    J Control Release; 2018 Jun; 279():89-98. PubMed ID: 29649530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.